ENDONOVO THERAPEUTICS, INC. Cash Flow Statement
ENDV|9 years of annual SEC 10-K data (FY2011-FY2022)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 9 fiscal years. All figures from audited SEC 10-K filings.
ENDONOVO THERAPEUTICS, INC. used $678,838 in operating cash flow in FY2022.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2016 | FY2015 | FY2014 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$18.5M | -$3.1M | -$395.6K | -$17.3M | -$6.4M | -$5.3M | -$6.8M | -$959.5K | -$94.1K |
| Depreciation & Amortization | $646.9K | $648.5K | $651.2K | $650.3K | $650.2K | $15.8K | $14.8K | $15.7K | $979 |
| Operating Cash Flow | -$678.8K | -$986.6K | -$741.6K | -$2.5M | -$2.9M | -$2.5M | -$1.0M | -$909.3K | -$50.4K |
| Capital Expenditures | - | - | - | $2.6K | $9.0K | - | $3.8K | $0 | - |
| Free Cash Flow | - | - | - | -$2.5M | -$2.9M | - | -$1.0M | -$909.3K | - |
| FCF Margin | - | - | - | -820.1% | -3468.3% | - | -23989.8% | -3758.7% | - |